950769-76-3

Upstream product

• 55276-43-2 4-methanesulfonylpiperazine 
• 950769-74-1 7-(3-chloropropoxy)-2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazole 

Downstream Products

• 1191251-65-6 7-[3-(4-methanesulfonyl-piperazin-1-yl)-propoxy]-2-(4-aminophenyl)-imidazo[2,1-b][1,3]benzothiazole 

Relevant academic research and scientific papers

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2- morpholin-4-yl-ethoxy)imidazo-[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor

Treatment of AML patients with small molecule inhibitors of FLT3 kinase has been explored as a viable therapy. However, these agents are found to be less than optimal for the treatment of AML because of lack of sufficient potency or suboptimal oral pharma

Imidazolothiazole compounds for the treatment of disease

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.